Matinas BioPharma Reports Second Quarter 2023 Financial Resu

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...

Related Keywords

United States , New Jersey , Bedminster , American , Jody Cain , Matinas Biopharma , Jeromed Jabbour , National Resilience Inc , National Resilience , Development Authority , Access Program , European Congress , Matina Compassionate Expanded Use Program , Drug Administration , Population Pathway For Antifungals , Oral Amphotericinb Program , Key Program Updates , Matinas Biopharma Holdings Inc , Company Compassionate Expanded Use Access Program , Small Oligonucleotide Program , Biomedical Research , Compassionate Use Program , Expanded Use Program , Nationwide Children , Chief Executive Officer , Limited Population Pathway , Expanded Use Access Program , Clinical Microbiology , Infectious Disease , Expanded Access Program , Eunkyung Song , Private Securities Litigation Reform Act , Biopharma Holdings , Consolidated Statements , Markets ,